scPharmaceuticals, Inc. (SCPH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lexicon Pharmaceuticals, Inc.

IGM Biosciences, Inc.

scPharmaceuticals, Inc.

Ovid Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

AC Immune SA

Compass Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

Inozyme Pharma, Inc.

Atea Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

Why is scPharmaceuticals, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -167.77% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -9.56

With a growth in Net Sales of 99.17%, the company declared Very Positive results in Jun 25

ROCE(HY) Highest at 0%
INVENTORY TURNOVER RATIO(HY) Highest at 1.06 times
NET SALES(Q) Highest at USD 16.04 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 42.64%, its profits have fallen by -20.3%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 42.64% in the last 1 year, much higher than market (S&P 500) returns of 18.33%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to scPharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is scPharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

scPharmaceuticals, Inc.

42.64%

0.54

69.36%

S&P 500

13.22%

0.91

20.14%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

119.51%

EBIT Growth (5y)

-167.77%

EBIT to Interest (avg)

-9.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.22

Sales to Capital Employed (avg)

0.46

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-43.25

EV to EBIT

-3.23

EV to EBITDA

-3.24

EV to Capital Employed

-18.96

EV to Sales

5.13

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company

ROCE(HY)

Highest at 0%

INVENTORY TURNOVER RATIO(HY)

Highest at 1.06 times

NET SALES(Q)

Highest at USD 16.04 MM

OPERATING PROFIT(Q)

Highest at USD -14.23 MM

OPERATING PROFIT MARGIN(Q)

Highest at -88.71 %

PRE-TAX PROFIT(Q)

Highest at USD -15.31 MM

NET PROFIT(Q)

Highest at USD -15.31 MM

EPS(Q)

Highest at USD -0.34

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.92 times

Here's what is working for scPharmaceuticals, Inc.

Net Sales

At USD 16.04 MM has Grown at 99.17%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

Highest at USD 16.04 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -14.23 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -88.71 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -15.31 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -15.31 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.34

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Highest at 1.06 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for scPharmaceuticals, Inc.

Debtors Turnover Ratio

Lowest at 3.92 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio